Phase II Trial of Nivolumab plus Ipilimumab in Patients with Renal Medullary Carcinoma
MD Anderson Study Status
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with kidney cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Information and next steps
Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Genitourinary Medical Oncology
For general questions about clinical trials: